Combination drug therapy for relapsed T-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs—mitoxantrone hydrochloride liposome and enlonstobart—for people with peripheral T-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of peripheral T-cell lymphoma (PTCL) that has relapsed or is resistant to treatment.
- You must be in generally good health, with adequate organ and bone marrow function.
- You cannot have had certain prior treatments, such as high doses of anthracyclines or prior failure with mitoxantrone.
- You must be willing to use effective contraception if you are of childbearing potential.
- You must not have active infections like hepatitis B or C, or other serious medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination therapy with tazemetostat for people whose peripheral T-cell lymphoma has come back or hasn't responded to previous treatment. The goal is to see if this drug combination can help shrink tumors or slow the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This clinical trial tests a new combination of two drugs (SHR2554 and liposomal mitoxantrone) as a first treatment for adults with certain types of peripheral T-cell lymphoma. The goal is to see if this combination is safe and effective.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
Hear when a new Relapsed or Refractory Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.